Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 317 of 5804
-
New hope for transplant patients: shorter drug course may beat stubborn virus
Disease control Recruiting nowTo comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New stem cell transplant could help more blood cancer patients find a donor
Disease control Not yet recruitingThis is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Phase: NA • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the safety and efficacy of CAR-ITNK cells therapy targeting CD70 and CLL1 in participants with relapsed/refractory Acute Myeloid Leukemia. Participants will receive a single infusion of CAR-ITNK cell therapy targeting CD70 and CLL…
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug duo aims to extend remission in advanced ovarian cancer
Disease control Not yet recruitingThis is a single-arm, open-label, multicenter exploratory clinical study designed to evaluate the efficacy and safety of fluzoparib combined with famitinib malate as maintenance therapy in patients with newly diagnosed advanced (FIGO III-IV) high-grade serous or endometrioid ovar…
Phase: PHASE2 • Sponsor: Jinhua Zhou • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for advanced cervical cancer: drug combo trial launches
Disease control Not yet recruitingThis is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior…
Phase: PHASE3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could stem cell particles restore hearing? new trial begins.
Disease control Not yet recruitingThe goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to ans…
Phase: PHASE1, PHASE2 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Participants who have signed the informed consent form will undergo scree…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug duo targets hard-to-treat KRAS G12D cancers
Disease control Recruiting nowThis is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Brain stem cell injection aims to restore movement in Parkinson's
Disease control Not yet recruitingParkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments primarily manage symptoms but do not halt or reverse neuronal loss. Cellular repl…
Phase: PHASE1 • Sponsor: iCamuno Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for ovarian cancer: drug combo targets relapsed patients
Disease control Not yet recruitingThis study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
Phase: PHASE2 • Sponsor: Onconic Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer
Diagnosis Not yet recruitinga Phase II, single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.
Phase: PHASE2 • Sponsor: Haitao Niu, MD • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
Aging clock test: tirzepatide trial targets biological age
Disease control Recruiting nowThis pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg s…
Phase: PHASE2 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for stomach cancer: experimental drug combo targets tough tumors
Disease control Recruiting nowThis is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase: PHASE1, PHASE2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis. Patients will receive lymph node-sparing modified short-course radiotherapy combined with tislelizumab, C…
Phase: PHASE2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to outsmart Drug-Resistant breast cancer
Disease control Not yet recruitingThis study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. This study aims to investigate the efficacy and safety of Famitinib combination with SHR-A1811 in CDK4/6 inhibitors-resistent advanced HR+/HER2- breast cancer with SNF4 subtype.
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Promising new treatment for rare Muscle-Weakening disease enters human trials
Disease control Recruiting nowThis is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy. The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks comp…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for ovarian cancer: targeted drug T-DXd tested after standard treatments fail
Disease control Recruiting nowOvarian, fallopian tube, and peritoneal cancers are often diagnosed at an advanced stage, requiring chemotherapy. Recently, the standard treatment, platinum-based chemotherapy plus PARP inhibitors, has extended disease-free survival (PFS). However, most patients eventually develo…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for hepatitis delta: can switching drugs clear the virus?
Disease control Recruiting nowThis is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
Phase: PHASE2, PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Personalized cell therapy takes on advanced melanoma in new trial
Disease control Not yet recruitingThis is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced melanoma. A total of 90 participants are planned to b…
Phase: PHASE2 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
AI boosts colonoscopy: finding hidden cancer clues
Diagnosis Not yet recruitingThe investigators conducted a multicenter randomized controlled trial to explore the adjuvant effect of artificial intelligence in the detection of precancerous lesions in the proximal colon.This is a prospective, multicenter, single-blind, parallel randomized controlled trial.Du…
Sponsor: Limian Er • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC